- Pliaglis® Licensed in 15 New Countries - Minority Interest Acquisition of 6 Medical Aesthetic Clinics in Ontario - Deployment of Capital to...
Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita”), a growth-oriented, innovation-driven Canadian commercial dermatology company...
Enables Crescita to Participate in the Growing Medical Aesthetics Market Provides Commercial Platform for Crescita’s Medical and Aesthetic...
- Continued Expansion of Pliaglis® Worldwide - Strong Cash Balance of $13.1 Million - Growth in Manufacturing Segment due to New Purchase...
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial...
Positive Adjusted EBITDA1 and Strong Liquidity Position Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a...
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company, is pleased to...
F2020 Adjusted EBITDA1 of $3.2M Strong Ending Cash Position of $14.3M Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or...
Crescita Announces Filing of New Medical Device License Canada NewsWire LAVAL, QC, Jan. 21, 2021 Laboratoires...
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid Canada NewsWire LAVAL, QC, Nov. 26, 2020...
Crescita Reports Third Quarter 2020 Results Canada NewsWire LAVAL, QC, Nov. 12, 2020 Strong Ending Cash...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads